It is well known that reduced glomerular filtration rate (GFR) leads to an increased risk of 24 dyslipidemia, insulin resistance and cardiovascular mortality. The liver is a central organ for 25 metabolism, but its function in the uremic setting is still poorly characterized. We 26 used human primary hepatocytes isolated from livers of 9 donors with normal renal 27 function, to investigate perturbations in key metabolic pathways following exposure to 28 uremic (n=8) sera or healthy (n=8) sera, and to serum free control medium. Both uremic and 29 heathy elicited consistent responses from hepatocytes from multiple donors and as compared 30 to serum free control. However at physiological insulin concentrations uremic cells 31 accumulated 56% more intracellular lipids. Also, as comparing uremic to healthy medium 32 after culture, it contained more VLDL-TG and glucose. These changes were accompanied 33 by decreased phosphorylation of Akt S473 . mRNA levels of key regulators of 34 gluconeogenesis in uremic such as PCK-1 and G6P were elevated. We also found 35 increased expression of 11HSDB1 mRNA in uremic cells, along with high phosphorylation of 36 downstream p53 and PLC-γ1 Y783 . Thus, our ex vivo data suggests that the uremic hepatocytes 37 rapidly develops a glycogenic and lipogenic condition accompanied by perturbations in a 38 large number of signaling networks. 39 40
INTRODUCTION 48
Regardless of etiology, the loss of renal function (uremia) is also a state of dyslipidemia (7) 49 and insulin resistance (5, 11). Despite that non-diabetic uremic patients are commonly 50 euglycaemic, they exhibit increased circulating insulin levels and impaired glucose disposal 51 rate (5, 11). Furthermore, circulating lipids in uremic subjects are prevalently characterized by 52 an elevated presence of triglycerides (TGs), a reduced high density (HDL) and increased low 53 density (LDL) lipoprotein concentration (7, 11) . 54
Notwithstanding its' central role in metabolism, relatively little is known about hepatic 55 function under conditions of impaired renal functionality. Indirect measures appear to show a 56 normal glucose uptake and glycogen synthesis rate in the uremic liver (5), whereas decreased 57 levels of hepatic lecithin-cholesterol acyltransferase (LCAT) have been linked to low 58 circulating HDL in the same patient group (10). 59
Recently, Chapagain et al. (3) reported a central role for elevated hepatic 11β-hydroxysteroid 60
dehydrogenase (HSD) type 1, a determinant of intracellular cortisone signaling, in the 61 development of insulin resistance and dyslipidemia in two non-diabetic rodent models of 62 uremia. Notably, short-term administration of carbenoxolone, a specific 11β-HSD1 inhibitor, 63 resulted in normalization of glucose tolerance and circulating insulin levels, along with an 64
Western blot analysis 134
Human primary hepatocytes were washed twice in ice-cold PBS, then lysed in a lysis buffer 135 supplemented with protease and phosphatase inhibitors. . Protein assay kit (#500-0006; Bio 136 Rad) was used to determine protein concentration. SDS-PAGE was performed loading 40 µg 137 of protein onto each lane. Proteins were next transferred onto the nitrocellulose membranes 138 using the iBlot dry blotting system (#IB23001; Thermo Fisher Scientific). Membranes were 139 blocked with the StartingBlock blocking buffer (#37543; Thermo-Fisher Scientific) for 30 140 min at room temperature, incubated with primary antibodies overnight at 4° C, and secondary 141 antibodies for 2 h at room temperature. ECL, performed by using Super Signal West Dura 142
Extended Duration Substrate (Thermo Fisher Scientific) was used to reveal the bands, which 143
were detected with a Vilber Lourmat UV-instrument. Image J software was employed to 144 quantify band intensity (U.S. National Institutes of Health). 145
Antibodies were purchased from Cell Signaling Technology (Akt2 (D6G4) Rabbit mAb 146 (#3063); pAkt (Ser473) (D9E) rabbit mAb (#4060); pAkt (Thr450) Rabbit mAb (#12178); 147
Rabbit mAb (#12829); pFoxO1 (Thr24)/FoxO3a(Thr32) antibody (1:1000); Pan-Actin 149 (D18C11) Rabbit mAb (#9464)); anti-rabbit IgG HRP-linked secondary antibody (#7074). 150
151

Enzyme-linked immunoassay (ELISA) 152
The concentrations of ApoB in the cell media were measured using the Human ApoB ELISA 153 kit (#3715-1HP-2; Mabtech), whereas total-, phospho (Ser612)-and phospho (panTyr)-IRS-1 154
were analyzed with PathScan IRS-1 sandwich ELISA kits (#7328, #7332C and #7133C; Cell 155
Signaling Technology). 156 157
Phosphorylation profiling assay 158
The Proteome Profiler Human Phosphokinase array (#ARY003, R&D Systems) was used to 159 measure phosphorylation at 43 well-characterized intracellular signaling sites according to the 160 manufacturers' instructions. 161
162
Lipid staining 163
Intracellular lipid accumulation was assessed using the LipidTOX Green neutral lipid stain 164 (#H34475; Invitrogen). Cells were fixed with 4% formaldehyde for 20 min at room 165 temperature, washed three times with PBS, and then incubated with the dye for 40 min at 166 room temperature. Nuclei were stained using NucBlue Live Ready Probes Reagent (#R37605;Invitrogen 
Other laboratory analyses 180
Sera insulin, urea and total protein were evaluated using a Konelab 20XT centrifugal analyser 181 (Thermo Electron Corp.). Total TGs and very low density (VLDL)/LDL in cell culture media 182
were measured by fast protein liquid chromatography (FPLC) as previously described (13) . 183
Total bile acids were extracted from sera and media as previously described (2), measured 184 using GC-MS (6890 Network GC system/5973 Network mass selective detector, Agilent 185
Technologies) and quantified with MassHunter Workstation software (Agilent 186 Technologies). 187
188
Statistical analyses 189
Data are presented as mean ± SEM. Significance between groups was assessed using paired t-190 test after log transformation or one-way ANOVA (corrected for repeated measurement). 
RESULTS 215
Clinical and biochemical characterization of pooled sera. 216 8 patients with end-stage renal disease (ESRD) receiving maintenance hemodialysis as well as 217 8 approximately age-and gender-matched healthy subjects were enrolled as sera donors. 218
Clinical parameters and biochemical analyses were typical for the patient group ( Table 1) . 219
Briefly, fasting blood concentrations of insulin (but not glucose), triglycerides and cholesterol 220 as well as total bile acids were all higher in the sera from ESRD patients than in the sera from 221 healthy subjects. 222 223
Titration of incubation time and sera dose. 224
Cell viability at 0, 5, 10 and 20% sera was assessed by MTT assay ( Figure 1A) . No 225 differences in the high cell viability were observed with the tested sera concentrations. Next, 226
we tested the effect of sera concentrations and treatment times on hepatocellular expression. 227
Based on our hypothesis, we used mRNA levels of PCK1 and G6PC as markers of cell 228 dysmetabolism. As shown (Figure 1B, 1C) , all sera concentrations gave approximately the 229 same increase in mRNA levels in the uremic sera treated cells. No significant differences in 230 expression were observed at 1 and 6 h of incubation, whereas at 24 h a difference between 231 patient and control sera was visible. Based on the above, we elected to use the lowest 232 effective sera concentration and the longer incubation time. As shown in Figure 6A , mRNA levels of PCK1, a key regulator of gluconeogenesis, 265 increased significantly after uremic treatment in cells cultured with addition of either 0, 5, 10, 266 100nM insulin. Without insulin, we also measured increased mRNAs level of the 267 gluconeogenesis modulators (Figure 6B-D) . Briefly, expression levels of the key 268 gluconeogenic enzyme G6PC were markedly elevated in uremic sera treated cells, while 269 physiological insulin concentrations were only able to partly attenuate this difference. A 270 similar trend was observed with HNF4A, an upstream regulator of PCK1 and G6PC. The co-271 activator of PPAR-γ, PPARGC1A, decreased compared to serum free cells when healthy sera 272 was added, but remained unchanged in cells incubated with uremic sera. These differences 273 persisted at physiological, but not supra-physiological, insulin concentrations. 274
Genes of the insulin pathway were also analyzed. Compared to cells incubated with healthy 275 sera, incubated with uremic sera exhibited similar mRNA level of IRS1, PIK3R1, PIK3R2, or 276 FOXO1. mRNA of TRIB3 (Figure 6E ), SLC2A2 and GYS2 both increased by uremictreatment (data not shown). mRNA of HSD11B1 and HSD11B2 were significantly higher in 278 hepatocytes treated with uremic sera (Figure 7A, B) . 279
280
Induction of endoplasmatic reticulum (ER) stress transcripts. 281
Compared to cells incubated with healthy sera, uremic treated cells exhibited a slight increase 282 in sXBP1 but other markers (PRKCE, GRP78, ATF4, CHOP and Nrf2) of ER stress remained 283 unchanged at the mRNA level (Figure 8) . 284
285
Decreased hepatocyte Akt S473 phosphorylation under uremic conditions. 286
To assess insulin-signaling in the cells, we assessed Akt phosphorylation. pAkt S473 was less 287 abundant following uremic sera treatment, whereas no difference was observed in levels of 288 pAkt T450, pFOXO1 S256 , pFOXO3a T32 , pIRS-1 pan-Tyr or pIRS-1 S612 (Figure 9A-E) . 289
290
Incubation with uremic sera alters the phosphorylation of multiple signal mediators in a 291 reproducible manner. 292
To better understand the effect of uremic sera on hepatocytes ex vivo, we assessed the relative 293 phosphorylation of 43 kinases and 2 related proteins using a commercial immunoblotting 294 assay kit (Figure 10 ). Of these, P38α, HSP27, CREB, EGFR, P70S6 kinase, AMPKα, 295 Akt1/2/3 and STAT3 showed obviously less phosphorylation following incubation with 296 uremic sera, while the relative phosphorylation of Src and PLC-γ1 were increased. 297
DISCUSSION 299
We investigated metabolic phenotypes and selected signaling pathways in human primary 300 hepatocytes following exposure to sera from individuals with advanced non-diabetic CKD 301 and healthy controls. Although simple, our study comprises what to our knowledge is the first 302 characterization of human hepatocytes under uremic conditions to date and it evoked a 303 phenotype surprisingly like that seen in the clinical setting (5, 7, 11, 14) and in rodent models 304 of uremia (1, 3, 8) . 305
Following exposure to 24 hours of either healthy or uremic sera, the hepatocytes (all from 306 non-uremic donors) demonstrated a maintained glycogenolysis that responded to cAMP but 307 not insulin. The lack of insulin response could probably be explained by the lack of glucose 308 substrate in the media, which may necessitate a continued glycogen breakdown. analysis of culture media revealed increased secretion of VLDL-TG in this group. These 318 changes were matched by an increase in ApoB mRNA in uremic sera treated cells, but 319 surprisingly media ApoB levels did not change, perhaps suggesting a possible role for a post-320 translational but pre-secretory regulation (12). Expression analyses also showed the induction 321 of lipogenesis in hepatocytes exposed to uremic sera compared to healthy sera treated cells, 322 including significant increases in mRNA of several key lipogenic genes (SREBF1, FASN,  323 ChREBP, DGAT1, CIDEC) and, somewhat unexpectedly, also of genes involved in lipolysis 324 (LIPC, PPARA, CPT1A, FABP1) and lipoprotein uptake (LDLR, LRP1). The physiological 325 relevance of these finding remains to be elucidated in the future study. 326
The described metabolic differences persisted also after dialysis of all sera and were evident 327 already at a 1:20 sera dilution, leading us to hypothesize that they might be mediated by 328 specific signals amplified at or beyond the cell membrane rather than by non-specific 329 disturbances in for example pH or salts.
It is interesting to note the clear similarities between our data and those recently reported by 331
Chapagain et al. (3) in two mouse models of uremia. That same study also found elevations in 332 hepatic expression of 11β-hydroxysteroid dehydrogenase (HSD) type 1, a key enzyme for 333 cortisol biosynthesis, and reported that treatment with an inhibitor of this enzyme led to the 334 normalization of hepatic transcription in uremic animals. An elevated 11β-HSD1 mRNA was 335 observed as part of the uremic phenotype also in the present study. Chapagain et al. 336 speculated that inflammation could be one factor behind the observed increase in hepatic 11β-337 HSD1 in uremic animals. Indeed, studies in non-uremic settings have demonstrated two 338 linked mechanisms whereby such a signal could be mediated. First, the inflammatory 339 cytokines IL-1β and TNF-α may regulate 11β-HSD1 at the transcriptional level by p38 340 MAPK-C/EBPβ signaling and also indirectly through NF-kB (6) . Secondly, glucocorticoids 341 themselves potently increase 11beta-HSD1 expression in many cells, putatively through 342 pC/EBPα (17) as well as through the glucocorticoid receptor (GR) (18). Our data offers some 343 support for the involvement of one or more of these pathways, including increased 344 phosphorylation of p53 at the p38-specific S15 and S46 sites, as well as absent 345 dephosphorylation of pPLC-γ1 Y783 . 346 conditions. Primary human hepatocytes were treated with healthy or uremic sera during 24 h, 441 followed by washing with warm PBS twice to remove glucose. Cells were then incubated 442 with 100nM insulin for 15 min. Next, cAMP/dexamethasone was added for 3 h in glucose-443 free DMEM containing gluconeogenic substrate (sodium pyruvate). Glucose production was 444 assessed as gluconeogenesis (A) = total glucose production (with pyruvate) -glycogenolysis 445 (without pyruvate, B). * p<0.05. (n=3). 446 
